千亿·国际(中国)唯一官方网站
Other Affiliated Sites
Simplified Chinese
Traditional Chinese
About Hepalink
Group Profile
Corporate Philosophy
Milestones
Leadership Team
Scientific Advisory Board
Our Businesses
Heparin Business
Global Industrial Chain
Global Heparin Injections Business
Product Profile
CDMO Services
Innovative Drugs
Global Manufacturing
Company News
Investor Relations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Join Us
Career Development
Contact Us
Create Value for Investors Through
Safe and Stable Operations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Disclosures
A-Share Information
H-Share Information
A-Share Information
H-Share Information
2025.03.28
千亿国际：2024年度商誉减值测试报告
2025.03.28
千亿国际：2024年度监事会工作报告
2025.03.28
千亿国际：2024年年度报告
2025.03.28
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2024
2025.03.14
DATE OF BOARD MEETING
2025.02.26
VOLUNTARY ANNOUNCEMENT “ENOPARIN” OBTAINS APPROVAL FROM ARGENTINA
2025.02.26
千亿国际：关于依诺肝素钠注射液获得阿根廷药品注册批件的公告
2025.02.18
VOLUNTARY ANNOUNCEMENT H1710 INJECTION RECEIVED THE NOTICE OF APPROVAL FOR CLINI...
2025.02.18
千亿国际：关于获得药物临床试验批准通知书的公告
2025.02.14
VOLUNTARY ANNOUNCEMENT OBTAINING THE GMP CERTIFICATE FROM EMA
第一页
上一页
4
5
6
7
8
下一页
最后一页
About Hepalink
Group Profile
Corporate Philosophy
Milestones
Leadership Team
Scientific Advisory Board
Our Businesses
Heparin Business
CDMO Services
Innovative Drugs
Global Manufacturing
Company News
Investor Relations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Join Us
Career Development
Contact Us
Official WeChat Account
Legal Statement
·
Environmental Disclosure
Copyright © 2024 Hepalink Group. All Rights Reserved.
